On February 14, according to the official website of Lianhua Electronics, an employee of its Suzhou 8-inch fab and ship chip manufacturing company was suspected of being infected with the new crown, and is currently cooperating with the local authorities to conduct full testing, production activities are gradually suspended, and after testing, it will fully resume work with the approval of the competent authorities.
UMC said that the monthly output value of Hejian Company accounted for about 5% of the overall consolidated revenue, and the company reiterated that the first quarter performance outlook remained unchanged, with the average price of the quarter rising by 5%, shipments being flat, and the quarterly gross profit margin of about 40%, accounting for the global wafer foundry industry market share will continue to expand. This incident has no material impact on the Company's financial operations. (End)
![Higher than Simcere Pharmaceutical's Xiannoxin, Junshi Biologics' new crown oral drug first price disclosure, 795 yuan / course of treatment[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)